Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of tungsten inhalation and continuous administration of angiotensin II on cardiac injury and pulmonary outcomes.

Toxicology and applied pharmacology·2026
Same author

After successful PCI for AMI and 1 mo of DAPT, P2Y12 inhibitor monotherapy was noninferior to continued DAPT for adverse outcomes.

Annals of internal medicine·2025
Same author

P2Y12 inhibitor monotherapy soon after PCI for ACS was not noninferior to DAPT for a composite of death or ischemic events.

Annals of internal medicine·2025
Same author

Cross-Cultural Exchange in Pharmacy Practice: An International APPE Experience in Japan.

American journal of pharmaceutical education·2025
Same author

Identifying Constrictive Pericarditis With Multimodality Imaging: A Diagnostic Challenge.

JACC. Case reports·2025
Same author

In subclinical AF, apixaban vs. aspirin reduced stroke or systemic embolism at 3.5 y, regardless of duration of recent subclinical AF episodes.

Annals of internal medicine·2025
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Loading, pretreatment, and interindividual variability issues with clopidogrel dosing

Eric R Bates, Wei C Lau, Barry E Bleske

    Circulation
    |May 25, 2005
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
    10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

    Microfluidics in Assessing Platelet Function
    06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    Related Experiment Videos

    Last Updated: Jun 23, 2026

    Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
    12:40

    Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

    Published on: December 7, 2012

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
    10:28

    Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

    Published on: March 15, 2022

    Microfluidics in Assessing Platelet Function
    06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024